Table 2.

Associations of total volume with demographic and clinical characteristics

	N	Median total vol	IQR	P-value
Sex				0.21b
Male	67	66	14, 116
Female	49	37	13, 79
Age				0.73c
≤59 yrs	41	49	15, 99
60–69 yrs	42	57	11, 111
≥70 yrs	33	58	15, 103
Primary				0.56b
Lung adeno	77	53	13, 105
Lung squam	33	63	28, 111
Lung poorly diff	6	28	10, 72
Best responsea				0.61c
PR	26	43	13, 88
SD	39	37	13, 79
PD	34	60	18, 84
Mets category				0.07c
M0/M1a	45	35	13, 72
M1b	12	59	22, 116
M1c	59	56	21, 128
Lines of previous Tx				0.70a
0	24	35	13, 115
1	64	60	15, 105
2 or more	28	71	13, 108
Agent				0.29b
Pembro	21	36	11, 70
Pembro + other	30	43	14, 132
Nivo	65	65	18, 116
On protocol				0.76b
No	71	51	13, 101
Yes	45	63	15, 123
Hospitalizations w/i 6 wksa				0.91b
No	78	47	13, 88
Yes	25	55	15, 80
Reason discontinuation				0.14b
PD, decline, PD-1 AE	96	56	15, 113
Completed therapy	11	36	7, 71
Other	7	193	2, 462
Unmeasurable lung				0.04b
No	27	71	36, 132
Yes	89	44	13, 92
Unmeasurable LN				0.33b
No	43	36	13, 84
Yes	73	61	14, 116
Unmeasurable liver				0.64b
No	93	55	13, 103
Yes	23	37	18, 138
Unmeasurable soft tissue				0.56b
No	85	63	13, 126
Yes	31	50	20, 79

Notes: ^aFor those followed for at least weeks; ^bKruskal–Wallis Test; ^cSpearman’s rank correlation.

Abbreviations: AE, adverse events; SD, stable disease; PD-1, program death-1; PR, partial response; LN, lymph node; PD, progression of disease.